Literature DB >> 902678

Dose-dependence of the pharmacokinetics of quinidine.

P Bolme, U Otto.   

Abstract

Quinidine was administrated orally to five healthy male volunteers. Doses of 0.2 g t.i.d., 0.3 g t.i.d. and 0.4 g t.i.d. were given for five days with at least four weeks between each test period. The plasma concentration of quinidine was measured before the morning dose on Days 2-5 of treatment, and 1, 2, 4 and 8 h after the morning dose on the 5th day. There was not a linear relationship between the increase in dose and the increase in plasma concentration of quinidine. A dose increase of 50% from 0.6 to 0.9 g quinidine sulphate per day resulted in an increase in steady state concentration of 94%. A further 33% increase in dose, from 0.9 to 1.2 g daily, resulted in a 55% increase in the steady state concentration of quinidine. The results demonstrate dose-dependent pharmacokinetics for quinidine. Possible explanations for the nonlinear pharmacokinetics are discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 902678     DOI: 10.1007/bf00561409

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  QUANTITATIVE DETERMINATION OF QUINIDINE IN PLASMA.

Authors:  G CRAMER; B ISAKSSON
Journal:  Scand J Clin Lab Invest       Date:  1963       Impact factor: 1.713

2.  Renal tubular secretion and reabsorption of organic bases in the dog.

Authors:  J TORRETTI; I M WEINER; G H MUDGE
Journal:  J Clin Invest       Date:  1962-04       Impact factor: 14.808

3.  Factors influencing conversion of chronic atrial fibrillation with special reference to serum quinidine concentration.

Authors:  R E BALL; M SOKOLOW
Journal:  Circulation       Date:  1956-10       Impact factor: 29.690

4.  Serum quinidine levels after administration of three different quinidine preparations.

Authors:  R Henning; G Nyberg
Journal:  Eur J Clin Pharmacol       Date:  1973-12       Impact factor: 2.953

5.  Quinidine excretion in aciduria and alkaluria.

Authors:  R E Gerhardt; R F Knouss; P T Thyrum; R J Luchi; J J Morris
Journal:  Ann Intern Med       Date:  1969-11       Impact factor: 25.391

6.  Early and late results of conversion of atrial fibrillation with quinidine. A clinical and hemodynamic study.

Authors:  G Cramér
Journal:  Acta Med Scand Suppl       Date:  1968

7.  Serum-phenytoin levels in management of epilepsy.

Authors:  A Richens; A Dunlop
Journal:  Lancet       Date:  1975-08-09       Impact factor: 79.321

8.  Absolute quinidine bioavailability.

Authors:  C T Ueda; B J Williamson; B S Dzindzio
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

9.  Quinine-induced alterations in drug disposition.

Authors:  C M Berlin; J M Stackman; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

10.  Disposition kinetics of two oral forms of quinidine.

Authors:  W A Mahon; M Mayersohn; T Inaba
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

  10 in total
  5 in total

1.  Pharmacokinetics of quinidine related to plasma protein binding in man.

Authors:  D Fremstad; O G Nilsen; L Storstein; J Amlie; S Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  1979-04-17       Impact factor: 2.953

2.  The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine.

Authors:  R A Wooding-Scott; J Smalley; J Visco; R L Slaughter
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

3.  Absorption of quinidine from an enteric-coated preparation.

Authors:  D Fremstad; O G Nilsen; J Amlie; L Storstein; B Olsson; S Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

5.  Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies.

Authors:  T W Guentert; N H Holford; P E Coates; R A Upton; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1979-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.